Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Bank of America Global Healthcare Conference Transcript

May 11, 2023 / 12:00AM GMT
Release Date Price: €17.5 (+2.94%)
Alec Warren Stranahan
BofA Securities, Research Division - Associate

Okay. So let's get going. Hey, everyone, good afternoon. Welcome to the last session of day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with REGENXBIO. My name is Alec Stranahan, I'm a Vice President and Senior Biotech Analyst covering REGENX here at BofA.

And I'm pleased to be joined by Ken Mills, President and Chief Executive Officer of REGENXBIO, as well as Steve Pakola, REGENXBIO's Chief Medical Officer. Thanks for being here, guys.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Thanks for having us.

Alec Warren Stranahan
BofA Securities, Research Division - Associate

Great. So Ken, do you want to maybe kick off with some prepared remarks and then we can jump into the Q&A.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

We're even unprepared. Either way, I think there'll be something that I hope lands well on folks. It's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot